EQUIVALENCE STUDY OF IMMEDIATE RELEASE TABLETS OF BETA BLOCKER DRUG
Objective: The therapeutic equivalence of generic brands is a great challenge for manufacturers. This study aimed to evaluate the bioequivalence of four different generic brands of atenolol tablets under biowaiver conditions.
Methods: Physiochemical properties of the tablet products namely uniformity of weight, hardness, disintegration, and drug content were assessed. The dissolution profiles of atenolol tablets were conducted in pH 1.2, 4.5, 6.8 and 7.6 buffers using USP dissolution apparatus II. Similarity and difference factors were calculated. Finally, four kinetic models have been offered to describe the release characteristics of atenolol under experiment conditions.
Results: All tablets showed accepted physiochemical characters. Dissolution profiles revealed that G2 showed the highest similarity to innovator (f2 91.86) in pH 7.6. Dissolution kinetics of G2 at the same pH could be best described as Higuchi model of release.
Conclusion: The study showed that excipients and manufacturing practices play an important role in marketing biowaiver generic products meet the international regulatory bodies criteria.
2. Kalantzi L, Reppas C, Dressman JB, Amidon G, Junginger HE, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci 2006;95:4–14.
3. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends, DM. Biowaiver monographs for immediate release solid oral dosage forms based on a biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate and chloroquine hydrochloride. J Pharm Sci 2005;94:1389–95.
4. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 2005;94:2121–31.
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennerna H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85–96.
6. Kortejarvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J Pharm Sci 2005;94:1617–25.
7. FDA. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Food and Drug Administration, Center for Drug Evaluation and Research USA; 2000. Available from: http://www.fda.gov/cder/ guidance/3618fnl.pdf. [Last accessed on 10 Oct 2019].
8. WHO. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Working document AS/04.093/Rev.4. World Health Organization; 2005. Available from: http://www.who.int/medicines/ services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf [Last accessed on 10 Oct 2019].
9. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002;19:921–5.
10. Bergstrom CA, Luthman K, Artursson P. Accuracy of calculated pH-dependent aqueous drug solubility. Eur J Pharm Sci 2004;22:387–98.
11. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265–8.
12. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11–23.
13. The Merck Index. Version 12.1 on CD-ROM. Merck and Co., Whitehouse Station NJ, USA; 1996. p. 1151-63.
14. Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, et al. Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate. J Pharm Sci 2012;101:936-45.
15. Hassan HA, Charoo NA, Ali AA, Alkhatem SS. Establishment of bioequivalence indicating dissolution specification for candesartan cilexetil tablets using a convolution model. Dissolution Technol 2015;36-45. Doi.org/10.14227/ DT220115P36.
16. Qureshi SA. In vitro-in vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing–a simple and practical approach. Open Drug Delivery J 2010;4:38-47.
17. Blume EJ, Schug BS. The biopharmaceutical classification system (BCS): class III drugs-better candidates for BA/BE waiver? Eur J Pharm Sci 1999;9:117–21.
18. Nani P, Karina CR, Eilany M. The effect of co-processed super disintegrants ratio (crospovidone-sodium starch glycolate) to the physicochemical characteristics of atenolol orally disintegrating tablets. Asian J Pharm Clin Res 2018;11:318-24.
19. Hamad I, Arida A, Al-Tabakha M. Effect of the lubricant magnesium stearate on changes of the specific surface area of directly compressible powders under compression. Jordan J Pharm Sci 2015;8:21–33.
20. Reddy NH, Patnala S, Kanfer I. Investigation of biowaivers for immediate release formulations containing BCS III drugs, acyclovir, atenolol, and ciprofloxacin hydrochloride, using dissolution testing. AAPS PharmSciTech 2017;18:424-31.
21. Kumare MM, Marathe RP, Kawade RM, Ghante MH, Shendarkar RR. Design of fast dissolving tablet of atenolol using novel co-processed super disintegrants. Asian J Pharm Clin Res 2013;3:81-5.
22. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK. Biowaiver monographs for immediate release solid oral dosage forms based on a biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 2004;93:1945–56.
23. Granero GE, Longhi MR, Junginger HE. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci 2010;99:2544-56.
24. Dressman JB, Nair A, Abrahamsson B, Barends DM, Groot DW. Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid. J Pharm Sci 2012;101:2653-67.
25. United State Pharmacopoeia 24. United state pharmacopoeial convection. 4th edition. Pharmaceutical Press. London; 2003. p. 237-41.
26. British Pharmacopoeia Volume I and II. British Pharmacopoeia Commission. The stationery office limited, London; 2007. p. 249–67.
27. Rowe R, Sheske P, Weller P. Handbook of pharmaceutical excipients. In: Rockvilled MD. Asian edition; 2000. p. 843-65.
28. World Health Organization. Guidance on waiver of in vivo bioequivalence requirements. Available from: http://apps. who.int/medicinedocs/documents/s23056en/s23056en.pdf. [Last accessed 08 Sep 2019].
29. Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 2001;220:77–83.
30. Costa P, Lobo J. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–33.
31. Higuchi T. Mechanism of sustained action medication. Theoretical analysis of the rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145–9.
32. Ritger RL, Peppas NA. A simple equation for the description of solute release. II. Fickian and anomalous release from swellable devices. J Controlled Release 1987;5:37–42.
33. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Tech 1996;20:64–74.
This work is licensed under a Creative Commons Attribution 4.0 International License.